-
Je něco špatně v tomto záznamu ?
Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial
R. Schäfer, V. Strnad, C. Polgár, W. Uter, G. Hildebrandt, OJ. Ott, D. Kauer-Dorner, H. Knauerhase, T. Major, J. Lyczek, JL. Guinot, J. Dunst, CG. Miguelez, P. Slampa, M. Allgäuer, K. Lössl, G. Kovács, AR. Fischedick, R. Fietkau, A. Resch, A....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
NLK
ProQuest Central
od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
- MeSH
- adjuvantní radioterapie MeSH
- brachyterapie škodlivé účinky metody MeSH
- časové faktory MeSH
- dospělí MeSH
- karcinom patologie terapie MeSH
- kvalita života * MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory prsu patologie terapie MeSH
- průzkumy a dotazníky MeSH
- segmentální mastektomie * škodlivé účinky MeSH
- senioři MeSH
- staging nádorů MeSH
- stupeň nádoru MeSH
- výsledek terapie MeSH
- zdravotní stav MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: Previous results from the GEC-ESTRO trial showed that accelerated partial breast irradiation (APBI) using multicatheter brachytherapy in the treatment of early breast cancer after breast-conserving surgery was non-inferior to whole-breast irradiation in terms of local control and overall survival. Here, we present 5-year results of patient-reported quality of life. METHODS: We did this randomised controlled phase 3 trial at 16 hospitals and medical centres in seven European countries. Patients aged 40 years or older with 0-IIA breast cancer were randomly assigned (1:1) after breast-conserving surgery (resection margins ≥2 mm) to receive either whole-breast irradiation of 50 Gy with a boost of 10 Gy or APBI using multicatheter brachytherapy. Randomisation was stratified by study centre, tumour type, and menopausal status, with a block size of ten and an automated dynamic algorithm. There was no masking of patients or investigators. The primary endpoint of the trial was ipsilateral local recurrence. Here, we present 5-year results of quality of life (a prespecified secondary endpoint). Quality-of-life questionnaires (European Organisation for Research and Treatment of Cancer QLQ-C30, breast cancer module QLQ-BR23) were completed before radiotherapy (baseline 1), immediately after radiotherapy (baseline 2), and during follow-up. We analysed the data according to treatment received (as-treated population). Recruitment was completed in 2009, and long-term follow-up is continuing. The trial is registered at ClinicalTrials.gov, number NCT00402519. FINDINGS: Between April 20, 2004, and July 30, 2009, 633 patients had accelerated partial breast irradiation and 551 patients had whole-breast irradiation. Quality-of-life questionnaires at baseline 1 were available for 334 (53%) of 663 patients in the APBI group and 314 (57%) of 551 patients in the whole-breast irradiation group; the response rate was similar during follow-up. Global health status (range 0-100) was stable in both groups: at baseline 1, APBI group mean score 65·5 (SD 20·6) versus whole-breast irradiation group 64·6 (19·6), p=0·37; at 5 years, APBI group 66·2 (22·2) versus whole-breast irradiation group 66·0 (21·8), p=0·94. The only moderate, significant difference (difference of 10-20 points) between the groups was found in the breast symptoms scale. Breast symptom scores were significantly higher (ie, worse) after whole-breast irradiation than after APBI at baseline 2 (difference of means 13·6, 95% CI 9·7-17·5; p<0·0001) and at 3-month follow-up (difference of means 12·7, 95% CI 9·8-15·6; p<0·0001). INTERPRETATION: APBI with multicatheter brachytherapy was not associated with worse quality of life compared with whole-breast irradiation. This finding supports APBI as an alternative treatment option after breast-conserving surgery for patients with early breast cancer. FUNDING: German Cancer Aid.
Brachytherapy Department Centrum Onkologii Instytut im Marii Skłodowskiej Warsaw Poland
Center of Radiotherapy National Institute of Oncology Budapest Hungary
Department of Oncology Semmelweis University Budapest Hungary
Department of Radiation Oncology Catalan Institute of Oncology Barcelona Spain
Department of Radiation Oncology Clemens Hospital Münster Germany
Department of Radiation Oncology Hospital Barmherzige Brüder Regensburg Germany
Department of Radiation Oncology University Hospital AKH Wien Vienna Austria
Department of Radiation Oncology University Hospital Bern Inselspital Switzerland
Department of Radiation Oncology University Hospital Erlangen Erlangen Germany
Department of Radiation Oncology University Hospital Kiel Kiel Germany
Department of Radiation Oncology University Hospital Leipzig Leipzig Germany
Department of Radiation Oncology University Hospital Rostock Rostock Germany
Department of Radiation Oncology University Hospital Würzburg Würzburg Germany
Department of Radiation Oncology Valencian Institute of Oncology Valencia Spain
Department of Radiotherapy Sana Hospital Offenbach Offenbach Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028463
- 003
- CZ-PrNML
- 005
- 20190815105628.0
- 007
- ta
- 008
- 190813s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1470-2045(18)30195-5 $2 doi
- 035 __
- $a (PubMed)29695348
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Schäfer, Rebekka $u Department of Radiation Oncology, University Hospital Würzburg, Würzburg, Germany. Electronic address: schaefer_r2@ukw.de.
- 245 10
- $a Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial / $c R. Schäfer, V. Strnad, C. Polgár, W. Uter, G. Hildebrandt, OJ. Ott, D. Kauer-Dorner, H. Knauerhase, T. Major, J. Lyczek, JL. Guinot, J. Dunst, CG. Miguelez, P. Slampa, M. Allgäuer, K. Lössl, G. Kovács, AR. Fischedick, R. Fietkau, A. Resch, A. Kulik, L. Arribas, P. Niehoff, F. Guedea, A. Schlamann, C. Gall, B. Polat, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO),
- 520 9_
- $a BACKGROUND: Previous results from the GEC-ESTRO trial showed that accelerated partial breast irradiation (APBI) using multicatheter brachytherapy in the treatment of early breast cancer after breast-conserving surgery was non-inferior to whole-breast irradiation in terms of local control and overall survival. Here, we present 5-year results of patient-reported quality of life. METHODS: We did this randomised controlled phase 3 trial at 16 hospitals and medical centres in seven European countries. Patients aged 40 years or older with 0-IIA breast cancer were randomly assigned (1:1) after breast-conserving surgery (resection margins ≥2 mm) to receive either whole-breast irradiation of 50 Gy with a boost of 10 Gy or APBI using multicatheter brachytherapy. Randomisation was stratified by study centre, tumour type, and menopausal status, with a block size of ten and an automated dynamic algorithm. There was no masking of patients or investigators. The primary endpoint of the trial was ipsilateral local recurrence. Here, we present 5-year results of quality of life (a prespecified secondary endpoint). Quality-of-life questionnaires (European Organisation for Research and Treatment of Cancer QLQ-C30, breast cancer module QLQ-BR23) were completed before radiotherapy (baseline 1), immediately after radiotherapy (baseline 2), and during follow-up. We analysed the data according to treatment received (as-treated population). Recruitment was completed in 2009, and long-term follow-up is continuing. The trial is registered at ClinicalTrials.gov, number NCT00402519. FINDINGS: Between April 20, 2004, and July 30, 2009, 633 patients had accelerated partial breast irradiation and 551 patients had whole-breast irradiation. Quality-of-life questionnaires at baseline 1 were available for 334 (53%) of 663 patients in the APBI group and 314 (57%) of 551 patients in the whole-breast irradiation group; the response rate was similar during follow-up. Global health status (range 0-100) was stable in both groups: at baseline 1, APBI group mean score 65·5 (SD 20·6) versus whole-breast irradiation group 64·6 (19·6), p=0·37; at 5 years, APBI group 66·2 (22·2) versus whole-breast irradiation group 66·0 (21·8), p=0·94. The only moderate, significant difference (difference of 10-20 points) between the groups was found in the breast symptoms scale. Breast symptom scores were significantly higher (ie, worse) after whole-breast irradiation than after APBI at baseline 2 (difference of means 13·6, 95% CI 9·7-17·5; p<0·0001) and at 3-month follow-up (difference of means 12·7, 95% CI 9·8-15·6; p<0·0001). INTERPRETATION: APBI with multicatheter brachytherapy was not associated with worse quality of life compared with whole-breast irradiation. This finding supports APBI as an alternative treatment option after breast-conserving surgery for patients with early breast cancer. FUNDING: German Cancer Aid.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a brachyterapie $x škodlivé účinky $x metody $7 D001918
- 650 _2
- $a nádory prsu $x patologie $x terapie $7 D001943
- 650 _2
- $a karcinom $x patologie $x terapie $7 D002277
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a zdravotní stav $7 D006304
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a segmentální mastektomie $x škodlivé účinky $7 D015412
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a staging nádorů $7 D009367
- 650 12
- $a kvalita života $7 D011788
- 650 _2
- $a adjuvantní radioterapie $7 D018714
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Strnad, Vratislav $u Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany.
- 700 1_
- $a Polgár, Csaba $u Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary; Department of Oncology, Semmelweis University, Budapest, Hungary.
- 700 1_
- $a Uter, Wolfgang $u Department of Medical Informatics, Biometry and Epidemiology, University Erlangen-Nuremberg, Erlangen, Germany.
- 700 1_
- $a Hildebrandt, Guido $u Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany; Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany.
- 700 1_
- $a Ott, Oliver J $u Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany.
- 700 1_
- $a Kauer-Dorner, Daniela $u Department of Radiation Oncology, University Hospital AKH Wien, Vienna, Austria.
- 700 1_
- $a Knauerhase, Hellen $u Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany.
- 700 1_
- $a Major, Tibor $u Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
- 700 1_
- $a Lyczek, Jaroslaw $u Podkarpacki Hospital Cancer Center Brzozow, Brzozow, Poland; Brachytherapy Department, Centrum Onkologii-Instytut im Marii Skłodowskiej, Warsaw, Poland.
- 700 1_
- $a Guinot, Jose Luis $u Department of Radiation Oncology, Valencian Institute of Oncology, Valencia, Spain.
- 700 1_
- $a Dunst, Jürgen $u Department of Radiation Oncology, University Hospital Kiel, Kiel, Germany.
- 700 1_
- $a Miguelez, Cristina Gutierrez $u Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain.
- 700 1_
- $a Slampa, Pavel $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute and Faculty of Medicine, Brno, Czech Republic.
- 700 1_
- $a Allgäuer, Michael $u Department of Radiation Oncology, Hospital Barmherzige Brüder, Regensburg, Germany.
- 700 1_
- $a Lössl, Kristina $u Department of Radiation Oncology, University Hospital Bern, Inselspital, Switzerland.
- 700 1_
- $a Kovács, György $u Interdisciplinary Brachytherapy Unit, University of Lubeck/Universitätsklinikum Schleswig-Holstein Campus Lubeck, Lubeck, Germany.
- 700 1_
- $a Fischedick, Arnt-René $u Department of Radiation Oncology, Clemens Hospital, Münster, Germany.
- 700 1_
- $a Fietkau, Rainer $u Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany; Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany.
- 700 1_
- $a Resch, Alexandra $u Department of Radiation Oncology, University Hospital AKH Wien, Vienna, Austria.
- 700 1_
- $a Kulik, Anna $u Brachytherapy Department, Centrum Onkologii-Instytut im Marii Skłodowskiej, Warsaw, Poland.
- 700 1_
- $a Arribas, Leo $u Department of Radiation Oncology, Valencian Institute of Oncology, Valencia, Spain.
- 700 1_
- $a Niehoff, Peter $u Department of Radiation Oncology, University Hospital Kiel, Kiel, Germany; Department of Radiotherapy, Sana Hospital Offenbach, Offenbach, Germany.
- 700 1_
- $a Guedea, Ferran $u Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain.
- 700 1_
- $a Schlamann, Annika $u Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany.
- 700 1_
- $a Gall, Christine $u Department of Medical Informatics, Biometry and Epidemiology, University Erlangen-Nuremberg, Erlangen, Germany.
- 700 1_
- $a Polat, Bülent $u Department of Radiation Oncology, University Hospital Würzburg, Würzburg, Germany.
- 710 2_
- $a Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO)
- 773 0_
- $w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 19, č. 6 (2018), s. 834-844
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29695348 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190815105856 $b ABA008
- 999 __
- $a ok $b bmc $g 1433612 $s 1066923
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 19 $c 6 $d 834-844 $e 20180422 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
- LZP __
- $a Pubmed-20190813
